ARTICLE | Emerging Company Profile
Gyroscope complements dry AMD
Gyroscope's one-shot dry AMD therapy supplies an upstream complement factor
February 22, 2019 9:51 PM UTC
Gyroscope Therapeutics Ltd.’s complement-targeting gene therapy for dry age-related macular degeneration could have an edge over competing therapies that are dosed chronically or target complement downstream of its key immune mediators.
On Feb. 19, Gyroscope began Phase I/II testing of GT005, an undisclosed complement gene encoded in an adeno-associated viral (AAV) vector and administered via subretinal injection, for dry AMD. Syncona Ltd. launched Gyroscope in 2016 with $34.13 million in seed funding to develop the therapy. ...